Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05189496
Other study ID # KY-Q-2021-182
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2022
Est. completion date December 31, 2024

Study information

Verified date March 2022
Source Guangdong Provincial People's Hospital
Contact Kun Wang
Phone 13922118086
Email gzwangkun@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Radiotherapy is one of the important treatments to improve the survival rate of breast cancer patients, but also has the risk of radiation lung injury, which can develop into pulmonary fibrosis. Hyperbaric oxygen can improve the tissue after radiation by promoting the function of vascular endothelial cells and fibroblasts, and reducing the secretion of inflammatory factors, thereby inhibiting the process of fibrosis and fiber atrophy after radiotherapy, and promoting tissue repair. Therefore, it has the potential value of treating chronic radiation injury. We aim to investigate whether hyperbaric oxygen treatment can reduce the incidence of radiation pneumonia and improve patients' quality of life, and to evaluate its safety and the impact on the patients' long-term survival outcomes.


Description:

Radiotherapy is one of the important treatments to improve the survival rate of breast cancer patients. Radiotherapy also has the risk of radiation lung injury, which can develop into pulmonary fibrosis, which seriously affects the quality of life of patients. Hyperbaric oxygen has received more attention in the field of delayed tissue damage caused by radiotherapy. In a hyperbaric oxygen environment, sufficient oxygen supply can improve the tissue after radiation by promoting the function of vascular endothelial cells and fibroblasts, and reducing the secretion of inflammatory factors. Low blood vessel density, low cell activity and low oxygen content in the "three low" state, thereby inhibiting the process of fibrosis and fiber atrophy after radiotherapy, and promoting tissue repair. Therefore, it has the potential value of treating chronic radiation injury. Can hyperbaric oxygen therapy be applied for breast cancer patients who were receiving radiotherapy, reduce the risk of radiation pneumonitis, prevent radiation pneumonitis and even radiofibrosis, and improve long-term survival? Therefore, we plan to prospectively enroll 380 breast cancer patients and randomly divide them into two groups. The treatment group will be given 30-40 hyperbaric oxygen therapy immediately after the end of radiotherapy, to study whether hyperbaric oxygen therapy reduces the risk of radiation pneumonia, and to evaluate hyperbaric oxygen The safety of treatment and its impact on the patient's quality of life and long-term survival outcomes provide an effective means to reduce the incidence of radiation pneumonia and improve the long-term quality of life.


Recruitment information / eligibility

Status Recruiting
Enrollment 380
Est. completion date December 31, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - (1) Volunteer to participate and sign informed consent in writing. (2) Past pathological diagnosis of breast cancer followed by radical treatment/surgery for breast cancer, followed by adjuvant chemotherapy followed by radiotherapy. (3) Excluding patients with simple neck lymph node recurrence and patients with distant metastases. (4) There is no secondary malignant tumor in other parts. (5) Age at entry = 18 years old and = 70 years old, both male and female. (6) The Eastern Cooperative Oncology Group (ECOG) has a performance status score of 0 or 1. (7) The expected survival period is =2 years. (8) There was no acute radiation lung injury in chest CT examination before and after radiotherapy Exclusion Criteria: - (1) Contraindications to hyperbaric oxygen therapy: lung disease (severe chronic obstructive airway disease, bullous lung disease, acute or chronic lung infection, uncontrolled asthma, untreated pneumothorax), in the past History of ear surgery, middle ear disease (eustachian tube dysfunction, recurrent dizziness), eye disease (retinal detachment). (2) Have received hyperbaric oxygen therapy in the past. (3) Radiation pneumonia had occurred at the time of enrollment or before receiving hyperbaric oxygen therapy. (4) Women who are pregnant or breastfeeding. (5) Patients who have not completed comprehensive breast cancer treatment due to disease progression, intolerable side effects, abandonment of treatment and other reasons. (8) Patients who need mechanical ventilation support. (9) Patients who cannot follow and understand simple commands. (10) Patients with disorientation and mental disorders.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
hyperbaric oxygen therapy
hyperbaric oxygen therapy

Locations

Country Name City State
China Guangdong Provincial People's Hospital Guangzhou Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Guangdong Provincial People's Hospital First Affiliated Hospital, Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of radiation pneumonitis Rate of enrolled participants with radiation pneumonitis 1 year
Secondary Grade of symptoms related to radiation pneumonitis The severity of symptoms (cough, shortness of breath, and so on) related to radiation pneumonitis, which is based on the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grading scale. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT02490319 - Study on the Biological Prediction Models of Radiation Pneumonitis
Recruiting NCT03803787 - Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients Phase 2
Completed NCT03796364 - Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis Phase 2
Not yet recruiting NCT04632342 - Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients Phase 2
Recruiting NCT05365802 - FAPI PET for Lung Fibrosis Early Phase 1
Completed NCT01754909 - Mitigation of Radiation Pneumonitis and Fibrosis Phase 2
Completed NCT01745484 - Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation N/A
Enrolling by invitation NCT02809456 - Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients Phase 2
Recruiting NCT00155909 - Risk Factors of Radiation Pneumonitis N/A
Recruiting NCT06069115 - Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort
Not yet recruiting NCT02296281 - Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury Phase 2
Completed NCT04863027 - Use of Dual Energy Computed Tomography in Thoracic Radiotherapy Planning.
Completed NCT03462524 - Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology N/A
Recruiting NCT05448703 - A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis
Recruiting NCT06079931 - The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia Phase 2
Recruiting NCT04676828 - Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer N/A
Recruiting NCT02735746 - Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis